Drug Profile
PD 3044
Alternative Names: PD-3044Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator P2D Bioscience
- Class Tropanes
- Mechanism of Action Dopamine receptor agonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA
- 21 Jul 2016 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)